| April 1 |
FDA Sends Boehringer Ingelheim Roxane Inc. Warning Letter for Marketing Unapproved New Drugs Roxanol Oral Solution, 20 mg/ml and Roxicodone Tablets, 5 mg |
| April 1 |
FDA Acts to Halt Marketing of Certain Unapproved Prescription Narcotic Drugs |
| April 1 |
TorreyPines Therapeutics Reduces Workforce to Three Employees |
| April 1 |
Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million |
| April 1 |
Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed |
| April 1 |
Medical Leaders to Propose Curbs on Conflict of Interest |
| April 1 |
Solvay Confirms It Is Proceeding With An Analysis Of Various Options For Its Pharmaceutical Activities |
| April 1 |
Global Market For Pediatric Healthcare Worth $79.2 Billion In 2013 |
| April 1 |
Stanford Medical School to Provide Online Disclosure of Faculty's Consulting Activities |
| April 2 |
Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols |
| April 2 |
Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL (lanthanum carbonate) Patents |
| April 2 |
Astellas Appoints New US President and CEO |
| April 2 |
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue |
| April 2 |
Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas |
| April 3 |
Charles River to Acquire Piedmont Research Center |
| April 3 |
PPD Acquires Magen BioSciences |
| April 3 |
R&D Directions’ Data Management For Clinical Trials Webinar Details Data Capture And Management Strategies |
| April 3 |
AstraZeneca's David Brennan Elected PhRMA Board Chairman |
| April 3 |
Pfizer Receives Request for Additional Information from FTC Regarding Proposed Acquisition of Wyeth |
| April 3 |
Pfizer Becomes The First Pharmaceutical Company To Be Accredited For Protection Of Human Rights In Clinical Research |
| April 6 |
U.S. Appeals Court Issues Ruling in Support of Lilly in Ariad Patent Litigation |
| April 6 |
Bristol-Myers Squibb Announces Extension of U.S. Agreement for Abilify and Establishment of an Oncology Collaboration with Otsuka |
| April 6 |
Statement Regarding Possible Offer for Renovo |
| April 6 |
FDA Sends Letters to 14 Companies Regarding Internet Ads |
| April 6 |
CVS Caremark Study Documents Changes in Prescription Drug Use to Treat High Blood Pressure, High Cholesterol and Diabetes in Children and Adolescents |
| April 7 |
Former Bristol-Myers Squibb Senior Executive Pleads Guilty for Role in Dishonest Dealings with the Federal Government |
| April 7 |
Diabetes and Blood Pressure Medication Prescriptions Increase Among Children and Teens |
| April 7 |
Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition |
| April 7 |
AstraZeneca Files Suit Against Apotex for a Declaratory Judgment of Infringement Against Pulmicort Respules Patents |
| April 7 |
AMA Announces Staff Reductions |
| April 7 |
2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics |
| April 7 |
Avalon Pharmaceuticals Receives Audit Opinion Containing Going Concern Statement |
| April 8 |
Manhattan Research Releases Digital DTC Relevance Rankings, Revealing Which Condition Groups Are Most Likely to Adopt eHealth |
| April 8 |
DDB Worldwide and M/A/R/C Research Find in Time of Economic Crisis: Health Is the New Wealth |
| April 8 |
Mylan Announces Clarinex Settlement Agreement |
| April 8 |
Governor, Legislature Support Sales Tax Exemptions For Clinical Trials and Free Samples of Drugs |
| April 8 |
J. Michael Cook to Retire from Lilly Board of Directors |
| April 8 |
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market |
| April 9 |
FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market |
| April 9 |
Inclusion of Untested Cancer Drug Clouds BC Government Announcement Recognizing Needs of Persons With Wet Age-Related Macular Degeneration |
| April 9 |
Sanofi-aventis to Acquire Medley in Brazil |
| April 9 |
New JHM Policies Tighten Rules on Industry Interactions |
| April 9 |
Heartburn Medications do not Ease Asthma Symptoms |
| April 10 |
Epocrates Alerts U.S. Physicians to Raptiva Recall Within Hours |
| April 10 |
FDA Obtains Permanent Injunction Barring Two Companies from Manufacturing and Distributing Unapproved Drugs |
| April 13 |
Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion |
| April 13 |
RegeneRx Announces Financing Transaction and Cost Reduction Program |
| April 13 |
PharmEng Announces Corporate Changes |
| April 13 |
Pill-Splitting Program Cut Member Out-of-Pocket Costs by $1.7 Million |
| April 14 |
Johnson & Johnson Reports 2009 First-Quarter Results |
| April 14 |
Physicians "Get Smart" - Number of Docs Using Smartphones Surges to 64% in 2009 |
| April 14 |
SpePharm Announces a Claim in Excess of 35 Million Euros Against BioAlliance Pharma For Breaking up Their Joint-Venture SpeBio |
| April 15 |
Sanofi-aventis to Acquire BiPar Sciences, a US Biopharmaceutical Company |
| April 15 |
Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 |
| April 15 |
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered |
| April 15 |
Significant Growth in the Pharmaceutical Industry Drives China Into Global Spotlight, Finds New PricewaterhouseCoopers Report |
| April 15 |
Roche and Genentech Announce Organizational and Leadership Decisions |
| April 16 |
Baxter Announces Strong First Quarter Financial Results |
| April 16 |
GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company |
| April 16 |
Biogen Idec Receives Approval for Tysabri High Titer Production |
| April 16 |
Roche strongly outperforms market in first quarter |
| April 16 |
Drug Marketing Disclosures Show Nearly $3 Million In Payments To Vermont Prescribers |
| April 16 |
Infinity Halts RING Trial in Advanced Gastrointestinal Stromal Tumors |
| April 16 |
PhRMA Statement on AARP Report |
| April 16 |
Kalorama Anticipates Increase in Rx-to-OTC Switches as Result of Recession |
| April 16 |
StemCells, Inc. Announces License Agreement with Major Pharmaceutical Company Covering Gene Insertion Technology |
| April 17 |
Amylin Pharmaceuticals Reports First Quarter Financial Results |
| April 17 |
Court Grants AstraZeneca Temporary Restraining Order Against Apotex in Pulmicort Respules Patent Litigation |
| April 17 |
One in Eight Pharmaceutical Sales Visits Are Impossible to Achieve, Says New Report from ZS |
| April 17 |
Discontinuation of Development of AC-3933, Therapeutic Agent for Dementia |
| April 17 |
Chiltern Acquires Brazil-Based Clinical Research Organization Vigiun |
| April 17 |
ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center |
| April 20 |
GlaxoSmithKline and Stiefel to Create New World-leading Specialist Dermatology Business |
| April 20 |
Lilly Reports Strong First-Quarter 2009 Results |
| April 20 |
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients |
| April 21 |
Schering-Plough Reports Financial Results for 2009 First Quarter |
| April 21 |
Merck Announces First-Quarter 2009 Financial Results |
| April 21 |
Healthline Launches Internet's First Treatment Search Tool; Healthline DocSearch Allows Consumers to Search; Compare and Connect to Relevant Specialists |
| April 21 |
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation |
| April 21 |
Boehringer Ingelheim Maintains its Growth Path in 2008 |
| April 21 |
Sanofi-Aventis Builds New Manufacturing Base in Hangzhou |
| April 21 |
Sanofi-Aventis Announces New Investment in China to Locally Produce Lantus SoloSTAR |
| April 21 |
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection |
| April 21 |
Icahn Responds to Cook and Wilson |
| April 21 |
Immtech to Reorganize Research and Development Operations |
| April 22 |
Genzyme Reports Solid Financial Results for the First Quarter of 2009 |
| April 22 |
Discontinuation of Development of TAK-379 for Treatment of Diabetes |
| April 23 |
Med Ad News Honors Healthcare Advertisers at 20th Annual Manny Awards |
| April 23 |
Pharmaceuticals Delivers Strong Underlying Growth in First Quarter of 2009 as Novartis Continues to Rejuvenate Product Portfolio |
| April 23 |
Updated FDA Action on Plan B (levonorgestrel) Tablets |
| April 23 |
IMS Health Lowers 2009 Global Pharmaceutical Market Forecast to 2.5 – 3.5 Percent Growth |
| April 23 |
Icahn Asks Amylin to Allow Discussions With Eastbourne |
| April 24 |
Amylin Issues Statement in Response to Carl Icahn |
| April 24 |
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08 |
| April 24 |
Sen. Grassley Works for Prescription Drug and Medical Device Safety |
| April 24 |
Iressa (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe |
| April 24 |
Ad hoc: Jerini AG: Management Board and Supervisory Board Decide to Wind Down the Operations of Jerini Ophthalmic, Inc. |
| April 24 |
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C |
| April 24 |
Abbott Annual Meeting Highlights Outstanding 2008 Results, Continued Strong Outlook |
| April 24 |
Eastbourne Capital Comments on Recent Developments Regarding Amylin Pharmaceuticals |
| April 24 |
Regional Biotech Association Warns Legislation Would Make VT Least Friendly State in Nation for Biotechnology and Life Sciences |
| April 24 |
Sucampo Acquires Rights to Rescula for U.S. and Canada |
| April 27 |
Q1/2009: Merck Revenues Remain Stable at € 1.9 Billion |
| April 27 |
Biogen Idec Board Recommends Shareholders Elect Directors with Record of Success in Enhancing the Value of the Company |
| April 27 |
SDI Reports Sixty-Seven Percent of Physicians Surveyed Have Positive Attitude Toward Electronic Promotional Activities |
| April 27 |
Concerned Shareholders of Biovail Announce - Independent Nominees for Election to Biovail Board of Directors - A Focused Commitment to Governance at Biovail |
| April 28 |
Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives |
| April 28 |
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer |
| April 28 |
Pfizer Reports First-Quarter 2009 Results; Reaffirms Full-Year 2009 Financial Guidance for Revenues and Adjusted Results |
| April 28 |
Kyowa Hakko Kirin Fiscal 2008 Sales up 17.4%, Operating Income up 15.2% |
| April 28 |
bioXell S.p.A (CH) - BioXell announces restructuring following review of portfolio |
| April 28 |
FDA Authorizes Emergency Use of Influenza Medicines, Diagnostic Test in Response to Swine Flu Outbreak in Humans |
| April 28 |
Pharmaceutical Industry Significantly Improves in Harris Interactive Reputation Study |
| April 28 |
Genaera Corporation Announces Approval of Plan of Liquidation and Dissolution by Board of Directors |
| April 29 |
PhRMA Applauds Kathleen Sebelius’ Confirmation as HHS Secretary |
| April 29 |
Sanofi-aventis Announces Good First-quarter 2009 Performance |
| April 29 |
Wyeth Reports Earnings Results for the 2009 First Quarter |
| April 29 |
MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology |
| April 29 |
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly |
| April 29 |
ZymoGenetics Announces Workforce Reduction and Restructuring |
| April 29 |
Statement from Roche Canada re: Supply of Tamiflu (oseltamivir) |
| April 29 |
Rx Response Raised to 'Alert Status' in Response to Growing Swine Flu Threat |
| April 30 |
AstraZeneca PLC First Quarter Results 2009 |
| April 30 |
Interim financial report for the period 1 January 2009 to 31 March 2009 (30 April 2009) |
| April 30 |
Shire Begins the Year with a Strong Performance |
| April 30 |
FDA MedWatch - Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B): Strengthened warnings in product labeling |
| April 30 |
Pharmaceutical Companies Are Looking to Reshape the Multi-Billion Dollar Drug Industry, Says New PricewaterhouseCoopers Report |
| April 30 |
FDA approves Exforge HCT - the only high blood pressure treatment to combine three medications in a single pill |
| April 30 |
Allergan Comments on FDA Requested Class Labeling for Botulinum Toxin Treatments in Connection with Approval of Dysport |
